Targeting the hypoxia-inducible factor (HIF) pathway in cancer

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Poon, Evon ^a   Harris, Adrian L ^b   Ashcroft, Margaret ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P53;

ANIMAL; CELL HYPOXIA; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROCOLLAGEN-PROLINE DIOXYGENASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350452792     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409001173     Document Type: Review

References (223)

1. Vaupel, P., Hockel, M. and Mayer, A. (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxidants and Redox Signalling 9, 1221-1235 (Pubitemid 47080831)
2. Hockel, M. et al. (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 26, 45-50 (Pubitemid 23063609)
3. Hockel, M. et al. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56, 4509-4515 (Pubitemid 26330463)
4. Hockel, M. et al. (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Research 59, 4525-4528 (Pubitemid 29428951)
5. Hockel, M. and Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93, 266-276 (Pubitemid 32219813)
6. Hockel, M. et al. (1993) Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecologic Oncology 51, 141-149 (Pubitemid 24020354)
7. Wang, G.L. et al. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America 92, 5510-5514
8. Guillemin, K. and Krasnow, M.A. (1997) The hypoxic response: huffing and HIFing. Cell 89, 9-12 (Pubitemid 27180579)
9. Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3, 721-732
10. Bos, R. et al. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 93, 309-314 (Pubitemid 32219818)
11. Zhong, H. et al. (1999) Overexpression of hypoxia-inducible factor-1alpha in common human cancers and their metastases. Cancer Research 59, 5830-5835
12. Maxwell, P.H. et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America 94, 8104-8109 (Pubitemid 27343784)
13. Staab, A. et al. (2007) Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer 7, 213
14. Williams, K.J. et al. (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology 75, 89-98 (Pubitemid 40616800)
15. Moeller, B.J. et al. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (Pubitemid 38610245)
16. Moeller, B.J. et al. (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110 (Pubitemid 41132739)
17. Jiang, B.H. et al. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. Journal of Biological Chemistry 271, 17771-17778
18. Li, H., Ko, H.P. and Whitlock, J.P. (1996) Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. Journal of Biological Chemistry 271, 21262-21267 (Pubitemid 26292983)
19. Fukuda, R. et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277, 38205-38211 (Pubitemid 35154674)
20. Laughner, E. et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 21, 3995-4004 (Pubitemid 32476461)
21. Huang, L.E. et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 95, 7987-7992
22. Ivan, M. et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468 (Pubitemid 32335941)
23. Jaakkola, P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (Pubitemid 32335942)
24. Masson, N. et al. (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO Journal 20, 5197-5206 (Pubitemid 32910914)
25. Yu, F. et al. (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98, 9630-9635 (Pubitemid 32769354)
26. Bruick, R.K. and McKnight, S.L. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (Pubitemid 33063099)
27. Epstein, A.C. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (Pubitemid 32972036)
28. Berra, E. et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO Journal 22, 4082-4090 (Pubitemid 37021737)
29. Kallio, P.J. et al. (1998) Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha EMBO Journal 17, 6573-6586 (Pubitemid 28521792)
30. Wang, G.L. and Semenza, G.L. (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 90, 4304-4308 (Pubitemid 23134215)
31. Hewitson, K.S. et al. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. Journal of Biological Chemistry 277, 26351-26355 (Pubitemid 34967127)
32. Lando, D. et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes and Development 16, 1466-1471 (Pubitemid 34686328)
33. Lando, D. et al. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861 (Pubitemid 34118367)
34. McNeill, L.A. et al. (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. The Biochemical Journal 367, 571-575 (Pubitemid 35305697)
35. Mahon, P.C., Hirota, K. and Semenza, G.L. (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes and Development 15, 2675-2686 (Pubitemid 32988878)
36. Semenza, G.L. (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 15, 551-578
37. Bardos, J.I. and Ashcroft, M. (2005) Negative and positive regulation of HIF-1: a complex network. Biochimica et Biophysica Acta 1755, 107-120 (Pubitemid 40982561)
38. Wiesener, M.S. et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92, 2260-2268 (Pubitemid 28452966)
39. Carroll, V.A. and Ashcroft, M. (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Research 66, 6264-6270
40. Compernolle, V. et al. (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Medicine 8, 702-710 (Pubitemid 34778723)
41. Hu, C.J. et al. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and Cellular Biology 23, 9361-9374
42. Krieg, M. et al. (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443 (Pubitemid 32000910)
43. Raval, R.R. et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 25, 5675-5686 (Pubitemid 40853601)
44. Maxwell, P.H. et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (Pubitemid 29246458)
45. Maynard, M.A. et al. (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 278, 11032-11040 (Pubitemid 36792653)
46. Makino, Y. et al. (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550-554 (Pubitemid 33131538)
47. Makino, Y. et al. (2007) Transcriptional upregulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. Journal of Biological Chemistry 282, 14073-14082 (Pubitemid 47100468)
48. Briere, J.J. et al. (2006) Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation.American Journal ofPhysiology - Cell Physiology 291, C1114-1120
49. Pollard, P.J. et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14, 2231-2239 (Pubitemid 41418022)
50. Berra, E., Pages, G. and Pouyssegur, J. (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer and Metastasis Reviews 19, 139-145 (Pubitemid 32004703)
51. Karni, R. et al. (2002) Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. Journal of Biological Chemistry 277, 42919-42925 (Pubitemid 35285669)
52. Lee, B.L. et al. (2008) A hypoxia-independent upregulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis 29, 44-51
53. Zhong, H. et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 60, 1541-1545 (Pubitemid 30183422)
54. Bardos, J.I. and Ashcroft, M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269 (Pubitemid 38325667)
55. Zundel, W. et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14, 391-396 (Pubitemid 30131884)
56. Miyake, K. et al. (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36, e1-9 (Pubitemid 351440946)
57. Koukourakis, M.I. et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 53, 1192-1202 (Pubitemid 34787855)
58. Winter, S.C. et al. (2006) The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107, 757-766 (Pubitemid 44232668)
59. Aebersold, D.M. et al. (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61, 2911-2916 (Pubitemid 32691934)
60. Bos, R. et al. (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581 (Pubitemid 36297788)
61. Gruber, G. et al. (2004) Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Research 6, R191-198
62. Klatte, T. et al. (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clinical Cancer Research 13, 7388-7393
63. Osada, R. et al. (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Human Pathology 38, 1310-1320 (Pubitemid 47247486)
64. Ke, H.L. et al. (2008) Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. International Journal of Urology 15, 200-205
65. Talks, K.L. et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. American Journal of Pathology 157, 411-421 (Pubitemid 30626905)
66. Fillies, T. et al. (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5, 84
67. Sumiyoshi, Y. et al. (2006) Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clinical Cancer Research 12, 5112-5117 (Pubitemid 44453338)
68. Maxwell, P.H. (2005) The HIF pathway in cancer. Seminars in Cell and Developmental Biology 16, 523-530
69. Bastien, L. et al. (2009) Targeted therapies in metastatic renal cancer in 2009. BJU International 103, 1334-42
70. Yeo, E.J., Chun, Y.S. and Park, J.W. (2004) New anticancer strategies targeting HIF-1. Biochemical Pharmacology 68, 1061-1069
71. Chen, J. et al. (2003) Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. American Journal of Pathology 162, 1283-1291 (Pubitemid 36350672)
72. Zinzalla, G. and Thurston, D.E. (2009) Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Medicinal Chemistry 1, 65-93
73. Kung, A.L. et al. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Medicine 6, 1335-1340 (Pubitemid 32001016)
74. Kung, A.L. et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxiainducible factor pathway. Cancer Cell 6, 33-43 (Pubitemid 38903160)
75. Li, S.H. et al. (2008)Anovel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1falphag. Molecular Cancer Therapeutics 7, 3729-3738
76. Yeo, E.J. et al. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 95, 516-525
77. Park, E.J. et al. (2006) Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5, 1847-1853
78. Erez, N. et al. (2003) Expression of prolylhydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Research 63, 8777-8783 (Pubitemid 38064057)
79. Choi, H.J. et al. (2008) Rapid degradation of hypoxia-inducible factor-1alpha by KRH10 2053, a new activator of prolyl hydroxylase 2. British Journal of Pharmacology 154, 114-125 (Pubitemid 351620399)
80. Nakayama, K. et al. (2004) Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117, 941-952 (Pubitemid 38798859)
81. Moller, A. et al. (2009) Inhibition of Siah ubiquitin ligase function. Oncogene 28, 289-296
82. Soussi, T. and Lozano, G. (2005) p53 mutation heterogeneity in cancer. Biochemical and BiophysicalResearchCommunications 331, 834-842 (Pubitemid 40615514)
83. Levine, A.J. (1997) p53 the cellular gatekeeper for growth and division. Cell 88, 323-331
84. Vousden, K.H. and Lane, D.P. (2007) p53 in health and disease. Nature Reviews Molecular Cell Biology 8, 275-283 (Pubitemid 46474662)
85. Denko, N.C. et al. (2000) p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Experimental Cell Research 258, 82-91 (Pubitemid 30461110)
86. Giaccia, A.J. and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes and Development 12, 2973-2983 (Pubitemid 28469299)
87. Graeber, T.G. et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (Pubitemid 26008141)
88. An, W.G. et al. (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408
89. Blagosklonny, M.V. et al. (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. Journal of Biological Chemistry 273, 11995-11998 (Pubitemid 28240554)
90. Ravi, R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes and Development 14, 34-44 (Pubitemid 30051577)
91. Yang, J. et al. (2009) Small molecule activation of p53 blocks HIF-1falphag and VEGF expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Molecular and Cellular Biology 29, 2243-2253
92. Sanchez-Puig, N.,Veprintsev, D.B. and Fersht, A.R. (2005) Binding of natively unfolded HIF-1alpha ODD domain to p53. Molecular Cell 17, 11-21 (Pubitemid 40075361)
93. Schmid, T. et al. (2004) p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). The Biochemical Journal 380, 289-295 (Pubitemid 38725754)
94. Chen, D. et al. (2003) Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. Journal of Biological Chemistry 278, 13595-13598 (Pubitemid 36799889)
95. Nieminen, A.L. et al. (2005)Mdm2and HIF-1alpha interaction in tumor cells during hypoxia. Journal of Cellular Physiology 204, 364-369
96. Bykov, V.J. and Wiman, K.G. (2003) Novel cancer therapy by reactivation of the p53 apoptosis pathway. Annals of Medicine 35, 458-465 (Pubitemid 37421557)
97. Foster, B.A. et al. (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510
98. Issaeva, N. et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Medicine 10, 1321-1328 (Pubitemid 40022713)
99. Vassilev, L.T. (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421
100. Chau, N.M. et al. (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxiainducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Research 65, 4918-4928
101. Tan, C. et al. (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Research 65, 605-612
102. Rapisarda, A. et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Research 62, 4316-4324 (Pubitemid 34827288)
103. Rapisarda, A. et al. (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Research 64, 6845-6848 (Pubitemid 39330988)
104. Koh, M.Y. et al. (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 7, 90-100
105. Macpherson, G.R. and Figg, W.D. (2004) Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biology and Therapy 3, 503-504 (Pubitemid 41351117)
106. Welsh, S. et al. (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 3, 233-244 (Pubitemid 39193698)
107. Manabe, H. et al. (2008) Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflammation Research 57, 4-10
108. Mie Lee, Y. et al. (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochemical and Biophysical Research Communications 300, 241-246
109. Sasakawa, Y. et al. (2003) Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Letters 195, 161-168 (Pubitemid 36588965)
110. Sasakawa, Y. et al. (2003) Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochemical Pharmacology 66, 897-906 (Pubitemid 37083586)
111. Yang, Q.C. et al. (2006) Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. Journal of Experimental and Clinical Cancer Research 25, 593-599 (Pubitemid 46170683)
112. Alqawi, O., Moghaddas, M. and Singh, G. (2006) Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer and Prostatic Diseases 9, 126-135 (Pubitemid 43970961)
113. Isaacs, J.S. et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. Journal of Biological Chemistry 277, 29936-29944
114. Kim,W.Y. et al. (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Research 69, 1624-1632
115. Lang, S.A. et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clinical Cancer Research 13, 6459-6468 (Pubitemid 350075036)
116. Liu, Y.V. et al. (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Molecular Cell 25, 207-217 (Pubitemid 46109612)
117. Zhang, H. et al. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America 105, 19579-19586
118. Gordan, J.D. et al. (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (Pubitemid 46518312)
119. Gordan, J.D. et al. (2008)HIF-alpha effects on c-Myc distinguish twosubtypes of sporadicVHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446
120. Chen, H.H. et al. (2007) Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Research and Treatment 103, 167-175 (Pubitemid 46789135)
121. Hara, S. et al. (2006) Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncology 42, 593-598 (Pubitemid 43947665)
122. Hayashi, M. et al. (2005) Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension. Endocrinology 146, 4682-4689 (Pubitemid 41446605)
123. Lim, J.H. et al. (2004) Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 23, 9427-9431
124. Giles, R.H. et al. (2006) Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25, 3065-3070 (Pubitemid 43780471)
125. Jiang,Y. et al. (2007) Hypoxia induces transforming growth factor-beta1 gene expression in the pulmonary artery of rats via hypoxia-inducible factor-1alpha. Acta Biochimica et Biophysica Sinica (Shanghai) 39, 73-80 (Pubitemid 46115039)
126. Kaidi, A., Williams, A.C. and Paraskeva, C. (2007) Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biology 9, 210-217 (Pubitemid 46420864)
127. Covello, K.L., Simon, M.C. and Keith, B. (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Research 65, 2277-2286 (Pubitemid 40490137)
128. Hu, C.J. et al. (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Molecular and Cellular Biology 26, 3514-3526
129. Sowter, H.M. et al. (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research 63, 6130-6134 (Pubitemid 37255150)
130. Rankin, E.B. et al. (2008) Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354-5358
131. Silva, P. et al. (2008) Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. International Journal of Radiation Oncology Biology Physics 72, 1551-1559
132. Tzao, C. et al. (2008) Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Disease Markers 25, 141-148
133. Uehara, M. et al. (2009) Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncology 45, 241-246
134. Trastour, C. et al. (2007) HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. International Journal of Cancer 120, 1451-1458 (Pubitemid 46355379)
135. Motzer, R.J. et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 356, 115-124 (Pubitemid 46089672)
136. Motzer, R.J. et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 16-24 (Pubitemid 46630489)
137. Ratain, M.J. et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24, 2505-2512 (Pubitemid 46630627)
138. O'Brien, M.F., Russo, P. and Motzer, R.J. (2008) Sunitinib therapy in renal cell carcinoma. BJU International 101, 1339-1342 (Pubitemid 351623982)
139. Turcotte, S. et al. (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14, 90-102 (Pubitemid 351885499)
140. Bommi-Reddy,A. et al. (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America 105, 16484-16489
141. Doll, C.M. et al. (2003) Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. International Journal of Radiation Oncology Biology Physics 55, 1239-1246 (Pubitemid 36338290)
142. Movsas, B. et al. (2001) Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. American Journal of Clinical Oncology 24, 458-461 (Pubitemid 32959102)
143. Kaanders, J.H. et al. (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research 62, 7066-7074 (Pubitemid 35424102)
144. Evans, S.M. et al. (2000) Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Research 60, 2018-2024 (Pubitemid 30207665)
145. Raleigh, J.A. et al. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Research 58, 3765-3768 (Pubitemid 28405626)
146. Brahme, A. (2003) Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncologica 42, 123-136
147. Padhani, A.R. et al. (2007) Imaging oxygenation of human tumours. European Radiology 17, 861-872 (Pubitemid 46772763)
148. Rajendran, J.G. and Krohn, K.A. (2005) Imaging hypoxia and angiogenesis in tumors. Radiologic Clinics of North America 43, 169-187 (Pubitemid 40326567)
149. Gagel, B. et al. (2006) [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6, 51
150. Rajendran, J.G. et al. (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clinical Cancer Research 12, 5435-5441 (Pubitemid 44497258)
151. Thorwarth, D. et al. (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiotherapy and Oncology 80, 151-156 (Pubitemid 44301544)
152. Troost, E.G. et al. (2008) Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging 35, 1803-1811
153. Hendriksen, E.M. et al. (2009) Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvascular Research 77, 96-103
154. Kong, D. et al. (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Research 65, 9047-9055 (Pubitemid 41377397)
155. Jones, D.T. and Harris, A.L. (2006) Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Molecular Cancer Therapeutics 5, 2193-2202 (Pubitemid 44530455)
156. Lin, X. et al. (2008) A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proceedings of the National Academy of Sciences of the United States of America 105, 174-179
157. Lee, K. et al. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proceedings of the National Academy of Sciences of the United States of America 106, 2353-2358
158. Greenberger, L.M. et al. (2008) A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 7, 3598-3608
159. Dikmen, Z.G. et al. (2008) In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 104, 985-994 (Pubitemid 351830845)
160. McEvoy, L.M. et al. (2005) HIF oligonucleotide decoy molecules. US Patent 056795
161. Buchler, P. et al. (2004) Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100, 201-210 (Pubitemid 37553556)
162. Sandau, K.B., Faus, H.G. and Brune, B. (2000) Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochemical and Biophysical Research Communications 278, 263-267
163. Sandau, K.B. et al. (2001) Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. Journal of Biological Chemistry 276, 39805-39811
164. Wang, B. et al. (2005) Genistein inhibited hypoxia-inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods and Findings in Experimental and Clinical Pharmacology 27, 179-184 (Pubitemid 40571212)
165. Calvani, M. et al. (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Research 68, 285-291 (Pubitemid 351380130)
166. Lu, Y. et al. (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Molecular Cancer 6, 63
167. Luwor, R.B. et al. (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24, 4433-4441 (Pubitemid 40961766)
168. Pore, N. et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Research 66, 3197-3204
169. Alam, H. et al. (2009) Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology 150, 915-928
170. Sutton, K.M. et al. (2007) Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 26, 3920-3929 (Pubitemid 46884295)
171. Kumar, S.M. et al. (2007) Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Research 67, 3177-3184 (Pubitemid 46724855)
172. Pore, N. et al. (2006) Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Research 66, 9252-9259 (Pubitemid 44521147)
173. Pore, N. et al. (2006) HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8, 889-895
174. Garcia-Maceira, P. and Mateo, J. (2009) Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28, 313-324
175. Stewart, G.D. et al. (2009) NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International Journal of Cancer 124, 223-232
176. Pencreach, E. et al. (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clinical Cancer Research 15, 1297-1307
177. Wang, W. et al. (2008) Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Digestive Diseases and Sciences Dec 4; [Epub ahead of print]
178. Wan, X. et al. (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8, 394-401 (Pubitemid 43830746)
179. Cejka, D. et al. (2008) Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biology and Therapy 7, 1377-1385
180. Mabuchi, S. et al. (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clinical Cancer Research 13, 4261-4270 (Pubitemid 47105991)
181. Fang, J. et al. (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28, 858-864 (Pubitemid 46523341)
182. Liu, L.Z. et al. (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Molecular Pharmacology 68, 635-643
183. Mirzoeva, S. et al. (2008) Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Molecular Carcinogenesis 47, 686-700
184. Osada, M., Imaoka, S. and Funae, Y. (2004) Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Letters 575, 59-63 (Pubitemid 39237681)
185. Kim, H.L. et al. (2006) A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. International Journal of Oncology 29, 255-260
186. Lau, C.K. et al. (2006) Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochemical and Biophysical Research Communications 348, 1443-1448 (Pubitemid 44291359)
187. Sun, H.L. et al. (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26, 3941-3951
188. Zhao, Q. et al. (2007) Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 34, 242-247 (Pubitemid 46294801)
189. Huang, S.P. et al. (2005) Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. Journal of Biomedical Science 12, 229-241
190. Jones, M.K. et al. (2002) von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB Journal 16, 264-266
191. Zhong, H.,Willard, M. and Simons, J. (2004) NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer 112, 585-595 (Pubitemid 39425938)
192. Palayoor, S.T., Tofilon, P.J. and Coleman, C.N. (2003) Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clinical Cancer Research 9, 3150-3157 (Pubitemid 37006311)
193. Fath, D.M. et al. (2006) Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. Journal of Biological Chemistry 281, 13612-13619 (Pubitemid 43855276)
194. Qian, D.Z. et al. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research 64, 6626-6634 (Pubitemid 39297923)
195. Thomas, S.L. et al. (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7, 2409-2417
196. Mabjeesh, N.J. et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375 (Pubitemid 38340305)
197. Mooberry, S.L. (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resistance Updates 6, 355-361
198. Ricker, J.L. et al. (2004) 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clinical Cancer Research 10, 8665-8673 (Pubitemid 40053435)
199. LaVallee, T.M. et al. (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Molecular Cancer Therapeutics 7, 1472-1482
200. Moser,C. et al. (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8, 206
201. Kim, H.S. et al. (2008) Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production. Pharmacology 81, 317-324 (Pubitemid 351666920)
202. Vlaminck, B. et al. (2007) Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS Journal 274, 5533-5542 (Pubitemid 47622065)
203. Olenyuk, B.Z. et al. (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America 101, 16768-16773 (Pubitemid 39601313)
204. Duyndam, M.C. et al. (2007) Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochemical Pharmacology 74, 191-201 (Pubitemid 46890812)
205. LaRusch, G.A. et al. (2007) Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Research 67, 450-454 (Pubitemid 46192180)
206. Jordan, B.F. et al. (2005) Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR in Biomedicine 18, 430-439 (Pubitemid 41646184)
207. Jordan, B.F. et al. (2005) Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7, 475-485 (Pubitemid 40796142)
208. Palayoor, S.T. et al. (2008) PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. International Journal of Cancer 123, 2430-2437
209. Werno, C., Zhou, J. and Brune, B. (2008) A23187, ionomycin and thapsigargin upregulate mRNA of HIF-1alpha via endoplasmic reticulum stress rather than a rise in intracellular calcium. Journal of Cellular Physiology 215, 708-714 (Pubitemid 351632692)
210. Zhu, K. et al. (2009) Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Research 69, 1836-1843
211. Rapisarda, A. and Melillo, G. (2007) UVC inhibits HIF-1alpha protein translation by a DNA damage-and topoisomerase I-independent pathway. Oncogene 26, 6875-6884 (Pubitemid 47609072)
212. Puppo, M. et al. (2008) Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Molecular Cancer Therapeutics 7, 1974-1984
213. Creighton-Gutteridge, M. et al. (2007) Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clinical Cancer Research 13, 1010-1018 (Pubitemid 46340380)
214. Kamiyama, H. et al. (2005) Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. Journal of Cancer Research and Clinical Oncology 131, 205-213 (Pubitemid 40238935)
215. Maeda, M. et al. (2006) Inhibition of angiogenesis andHIF-1alpha activity byantimycinA1.Biological and Pharmaceutical Bulletin 29, 1344-1348
216. Hagen, T. et al. (2003) Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302, 1975-1978 (Pubitemid 37523507)
217. Xia, C. et al. (2007) Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Research 67, 10823-10830 (Pubitemid 350145911)
218. Welsh, S.J. et al. (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics 2, 235-243
219. Groot, A.J. et al. (2008) Conditional inactivation of HIF-1 using intrabodies. Cellular Oncology 30, 397-409
220. Yasui, H. et al. (2008) Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. British Journal of Cancer 99, 1442-1452
221. Zeng, L. et al. (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Science 99, 2327-2335
222. Wu, H. et al. (2008) Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomedicine and Pharmacotherapy 62, 613-621
223. Newcomb, E.W. et al. (2005) Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-Oncology 7, 225-235 (Pubitemid 41079132)